Tiffany Olson is the President of Nuclear Pharmacy Services at Cardinal Health. Nuclear Pharmacy Services develops, manufactures, compounds, dispenses and delivers over 10 million time critical patient specific doses annually via a network of nuclear pharmacies and manufacturing sites that span the United States. Prior to Cardinal Health, Olson was President of NaviMed, a company focused on personalizing medicine through innovative diagnostics. She also worked for Eli Lilly and Company, where she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics. Olson worked for Roche Diagnostics for many years, where she attained the position of President and CEO of Roche Diagnostics Corporation. Prior to this appointment Olson was the Global Head of Market Development located in Basel, Switzerland. Other positions she held with the company included Vice President of Roche Molecular Diagnostics and Vice President of Corporate Accounts. She also spent a number of years in leading positions with other healthcare organizations. Olson was the first woman to receive the Life Science Alley Luminary Award, recognizing her “rich career in medical diagnostics…exceptional reputation as a leader and her vision to drive both innovation and value for personalized medicine.” In 2013, she received the “Woman of Wellness Award” for her extraordinary contributions in her volunteer work in oncology. She has written several articles on personalized medicine, molecular diagnostics and business strategy. Olson has a bachelor’s degree in business from the University of Minnesota and a master’s degree from St. Thomas University in Minnesota. She has held several board positions and currently serves as a Board Member for the Cardinal Health Foundation and Asuragen.

she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics.